From: Cognitive enhancing supplements and medications in United States Resident Physicians
Β | Prevalence (Nβ=β296) | |
---|---|---|
Supplements | % | 95% CI |
Noopept | 0.8% | (0.3%, 1.9%) |
Racetams | 3.3% | (1.9%, 5.1%) |
Ashwagandah | 3.8% | (2.3%, 5.7%) |
Bacopa monnieri | 0.5% | (0.1%, 1.3%) |
Caffeine | 78.4% | (74.7%, 81.9%) |
Creatine | 8.9% | (6.6%, 11.7%) |
Ginkgo biloba | 1.6% | (0.7%, 2.9%) |
Lionβs Mane Mushroom | 5.3% | (3.5%, 7.5%) |
L-theanine | 3.4% | (2.1%, 5.2%) |
Magnesium | 3.8% | (2.4%, 5.8%) |
Omega-3 fatty acids | 9.9% | (7.5%, 12.8%) |
Panax ginseng | 1.2% | (0.5%, 2.5%) |
Rhodiola rosea | 1.6% | (0.8%, 3.0%) |
Other | 4.7% | (3.0%, 6.8%) |
Medications | Β | Β |
Amphetamine | 19.2% | (15.9%, 22.9%) |
Methylphenidate | 6.3% | (4.4%, 8.7%) |
Modafinil | 11.1% | (8.5%, 14.0%) |
Cholinesterase inhibitor | 0.3% | (0.1%, 1.1%) |
Glutamate regulator | 0.00% | / |
Cholinesterase inhibitorβ+βglutamate regulator | 0.00% | / |